Five hundred twenty patients with de novo non-lymphocytic leukemia (ANLL) were classified according to morphocytochemical FAB criteria and then immunophenotyped using a set of 20 monoclonal antibodies (MoAb) of VI series. It was demonstrated that immunophenotyping increased the proportion of properly classified leukemias from 87% after morphocytochemical evaluation up to 97.5%. A first line diagnostic set was proposed for ANLL consisting of MoAbs detecting the following cell differentiation antigens: CDw65 (VIM2)--as a screening marker for the whole ANLL group, CD14 (VIM12)--as an indicator characteristic for M4 and M5 FAB subtypes, glycophorin A (VIEG4)--helpful in identification of erythroleukemia, CD15 (VIMD5)--which has a prognostic significance and CD41 (VIPI1)--important for identification of megacarioblastic M7 subtype. MoAbs detecting CD11b, CD61 and Ia-Dr may be used as the second line reagents.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process.
MAbs
December 2025
SeromYx Systems, Woburn, MA, USA.
The field of antibody therapeutics is rapidly growing, with over 210 antibodies currently approved or in regulatory review and ~ 1,250 antibodies in clinical development. Antibodies are highly versatile molecules that, with strategic design of their antigen-binding domain (Fab) and the domain responsible for mediating effector functions (Fc), can be used in a wide range of therapeutic indications. Building on many years of progress, the biopharmaceutical industry is now advancing innovative research and development by exploring new targets and new formats and using antibody engineering to fine-tune functions tailored to specific disease requirements.
View Article and Find Full Text PDFInformal care for people with dementia in Europe.
J Prev Alzheimers Dis
January 2025
Division of Neurogeriatrics, Department of Neurobiology Care Sciences and Society; Karolinska Institutet; Sweden; BioClinicum J9:20, Akademiska stråket, 171 64 Solna, Sweden.
Introduction: Informal care estimates for use in health-economic models are lacking. We aimed to estimate the association between informal care time and dementia symptoms across Europe.
Methods: A secondary analysis was performed on 13,529 observations in 5,369 persons from 9 European pooled cohort or trial studies in community-dwelling persons with dementia.
Early assessment of IL8 and PD1+ Treg predicts response and guides treatment monitoring in cemiplimab-treated cutaneous squamous cell carcinoma.
J Immunother Cancer
January 2025
Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
Purpose: Anti-programmed cell death 1 (PD1) is the first-choice treatment in patients with advanced cutaneous squamous cell carcinoma (cSCC), when curative options are unavailable. However, reliable biomarkers for patient selection are still lacking.
Experimental Design: In this translational study, clinical annotations, tissue and liquid biopsies were acquired to investigate the association between sustained objective responses and transcriptional profiles, immune cell dynamics in tumor tissue and peripheral blood samples, as well as circulating cytokine levels.
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
January 2025
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:
Background: Dermatomyositis is a chronic autoimmune disease with distinctive cutaneous eruptions and muscle weakness, and the pathophysiology is characterised by type I interferon (IFN) dysregulation. This study aims to assess the efficacy, safety, and target engagement of dazukibart, a potent, selective, humanised IgG1 neutralising monoclonal antibody directed against IFNβ, in adults with moderate-to-severe dermatomyositis.
Methods: This multicentre, double-blind, randomised, placebo-controlled, phase 2 trial was conducted at 25 university-based hospitals and outpatient sites in Germany, Hungary, Poland, Spain, and the USA.
Predicting purification process fit of monoclonal antibodies using machine learning.
MAbs
December 2025
Department of Purification, Microbiology and Virology, Genentech Inc, South San Francisco, CA, USA.
In early-stage development of therapeutic monoclonal antibodies, assessment of the viability and ease of their purification typically requires extensive experimentation. However, the work required for upstream protein expression and downstream purification development often conflicts with timeline pressures and material constraints, limiting the number of molecules and process conditions that can reasonably be assessed. Recently, high-throughput batch-binding screen data along with improved molecular descriptors have enabled development of robust quantitative structure-property relationship (QSPR) models that predict monoclonal antibody chromatographic binding behavior from the amino acid sequence.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!